Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas (NCT06303570).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial NCT06303570 (CBL-0202DD, placebo-controlled Phase 2) is recruiting, with primary completion est. Mar 2026. No results posted or announced. Positive readouts cited are from prior open-label Phase 2 (NCT05387733, CBL-0201DD, topline Sep 2023). No evidence of readout for this exact trial.

Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
ClinicalTrials.gov: NCT06303570 Study Details
Status: Recruiting. Primary Completion: Estimated 2026-03-01. No results posted.
Sponsorcaliwaybiopharma.comSep 13, 2023, 12:00 AM
Caliway: Positive Topline from CBL-514 Phase 2 for Dercum's (CBL-0201DD)
CBL-0201DD met primary/secondary endpoints: 64.5% lipomas complete clearance or >50% reduction, pain down 4.7 points. Planning CBL-0202DD placebo-controlled.
Web Searchprnewswire.comSep 13, 2023, 12:00 AM
PRNewswire: Caliway Phase 2 Topline for Dercum's Disease (CBL-0201DD)
Topline of CBL-0201DD: 64.5% lipomas clearance/>50% reduction, pain reduced 4.7 points. Planning CBL-0202DD Phase 2b IND.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

NCT06303570 (CBL-0202DD, Phase 2b placebo-controlled) is recruiting with estimated primary completion March 2026; no results posted. Positive topline data exists for a separate prior open-label Phase 2a (NCT05387733/CBL-0201DD, met endpoints with ~64.5% lipomas ≥50% reduction, significant pain relief), but this does not apply to the queried placebo-controlled trial.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchclinicaltrials.gov
A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
Recruiting. Estimated primary completion: 2026-03. No results posted. Primary endpoint: Partial Response (PR) by ultrasound at Week 20 vs placebo.
Web Searchbiospace.comSep 3, 2024, 12:00 AM
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease
CBL-0202DD (NCT06303570) is the randomized, placebo-controlled Phase 2b study. Results anticipated Q4 2025. References positive data from prior Phase 2 study only.
Web Searchcaliwaybiopharma.comSep 13, 2023, 12:00 AM
The Positive Topline Results from the CBL-514 Phase 2 Study for Dercum's Disease
Positive topline for prior CBL-0201DD Phase 2 (met all primary/secondary endpoints, 64.5% lipomas with ≥50% reduction or clearance, pain reduced 4.7 points). Different from NCT06303570.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found for NCT06303570. Sponsor materials say this Phase 2b study is still ongoing/recruiting, with topline/results expected later, so there is not enough evidence yet to classify the exact trial as positive or negative.

Found Apr 3, 2026, 4:30 PMReviewed Apr 3, 2026, 4:47 PM
Sponsorcaliwaybiopharma.com
CBL-514 R&D - Caliway Biopharmaceuticals
For Dercum’s disease, Caliway states the follow-up CBL-0202DD Phase 2b study is currently ongoing in the U.S., with topline results anticipated in Q3 2026.
Sponsorcaliwaybiopharma.comAug 26, 2024, 12:00 AM
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease
This sponsor release identifies CBL-0202DD / NCT06303570 as the Phase 2b study and says recruitment had started; results were anticipated in the future, not reported.
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No public Phase 2 readout for NCT06303570 was found. ClinicalTrials.gov still lists the trial as recruiting with no results posted, and sponsor communications describe it as an ongoing Phase 2b study with future statistical/readout timing rather than reported outcomes.

Found Apr 1, 2026, 7:16 PMReviewed Apr 1, 2026, 7:18 PM
ClinicalTrialsclinicaltrials.govAug 22, 2025, 12:00 AM
Study Details | NCT06303570 | A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
ClinicalTrials.gov shows NCT06303570 as Recruiting, with 'No Results Posted.' It lists estimated primary completion as 2026-03 and study completion as 2026-04.
Sponsorcaliwaybiopharma.comAug 26, 2024, 12:00 AM
Caliway Announces Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease
Sponsor said NCT06303570 had begun recruitment and expected statistical data in 2025 Q4, adding that timing could change. This is forward-looking and not a public efficacy readout.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.